OOIR: Observatory of International Research

Papers

(The TQCC of Clinical Gastroenterology and Hepatology is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Editorial Board	566
Front Cover	464
Hepatic Artery Pseudoaneurysm After Whipple Procedure	359
Table of Contents	302
Blue Notes	258
Editorial Board	241
Blue Notes	239
FODMAPs in IBS: Revisiting Restriction	210
Reply	206
Editorial Board	203
Nonalcoholic Fatty Liver Disease Natural History: Role of Mathematical Modeling	193
The Evolving Landscape of Colorectal Cancer Screening and Colonoscopy Practice: Insights From the Japan Polyp Study	183
Look for a Physical Health Status Surrogate in Hepatocellular Carcinoma: Have we Found the Holy Grail?	183
Reply	178
Relative Cost-effectiveness of Management Strategies for Uninvestigated Dyspepsia	153
Aseptic Abscess Syndrome With Ulcerative Colitis and Pyoderma Gangrenosum	153
Australasian Insights and Perspectives on the Burden of Chronic Liver Disease	144
Who Examines the Colon Matters More Than What Is Removed	140
High Hospitalization Rates and Risk Factors Among Frail Patients With Cirrhosis: A 10-year Population-based Cohort Study	139
Natural History of Patients Lost to Follow-up After Esophageal Food Impaction	137
Correction	134
Barrett’s Esophagus Risk Factors in Patients Without Gastroesophageal Reflux: A Large Population-Based Study	132
Table of Contents	131
Fecal Microbiota Transplantation (FMT) in Ulcerative Colitis: Holding Out for a Superdonor?	130
Overall and Annual Postcolonoscopy Colorectal Cancer Rates in a Large Integrated Healthcare Setting: A Cross-Sectional Study	130

Frequent Abnormal Pancreas Imaging in Patients With Pathogenic ATM, BRCA1, BRCA2, and PALB2 Breast Cancer Susceptibility Variants	129
Development of a Simple, Point-of-Care Device to Test Anorectal Function in Patients with Constipation: Randomized Clinical Trial	121
Endoscopic Ultrasound-Guided Portosystemic Pressure Gradient in Clinical Practice: An Investigational Procedure—What Can We Tell Patients?	119
Predictors of Placebo Induction Response and Remission in Ulcerative Colitis	119
The Diagnostic Performance of Fecal Immunochemical Tests for Detecting Advanced Neoplasia at Surveillance Colonoscopy	116
Symptom-Based Testing and Eradication of Helicobacter pylori and Risk of Gastric Cancer	115
Health Disparities in Inflammatory Bowel Disease Care Driven by Rural Versus Urban Residence: Challenges and Potential Solutions	114
Extended Risankizumab Treatment in Patients With Crohn’s Disease Who Did Not Achieve Clinical Response to Induction Treatment	110
Association of Statin Usage and the Development of Diabetes Mellitus after Acute Pancreatitis	110
Fecal Immunochemical Tests: The Right Colorectal Cancer Screening Test for the Average-Risk Population?	110
Ambulatory Acute Kidney Injury in Patients With Cirrhosis Is Common and Burdensome	104
Front Cover	102
Assessment and Significance of Histologic Activity in Crohn’s Disease	100
Reply	100
Hypermobile Ehlers-Danlos Syndrome and the Nosology of Disorders of Gut-Brain Interaction	99
Association Between Index Adenomas and Advanced Findings at Third Colonoscopy: Data From the New Hampshire Colonoscopy Registry	97
Blue Notes	97
Sugar-Sweetened Beverage, Diet Soda, and Nonalcoholic Fatty Liver Disease Over 6 Years: The Framingham Heart Study	95
Characterization of Prevalent, Post-Endoscopy, and Incident Esophageal Cancer in the United States: A Large Retrospective Cohort Study	95
Elsewhere in the AGA Journals	95
Hepatic Steatosis Is Associated With Increased Cardiovascular Risk Through Adverse Coronary Plaque Composition	93
Disaggregating Racial and Ethnic Data: A Step Toward Diversity, Equity, and Inclusion	92
Development of an MRI-Based Prediction Model for Anti-TNF Treatment Failure in Perianal Crohn’s Disease: A Multicenter Study	91
Low Daily Step Count Is Associated With a High Risk of Hospital Admission and Death in Community-Dwelling Patients With Cirrhosis	91
Long-term Effectiveness and Safety of Risankizumab in Patients With Crohn’s Disease	89
PErsistence and Safety of Subcutaneous Infliximab 1 Year After Switch From Intravenous Route in IBD Patients in REMission	89
An Approach to the Primary and Secondary Prevention of Gastric Cancer in the United States	88
Automated deep learning detection of hepatic steatosis on non-contrast CT scans and discrepancy with scan reports	88
Effectiveness of Reinduction and/or Dose Escalation of Ustekinumab in Crohn’s Disease: A Systematic Review and Meta-analysis	87
Update in the Treatment of the Complications of Cirrhosis	87
Low Incidence of Pulmonary Aspiration During Upper Endoscopy in Patients Prescribed a Glucagon-Like Peptide 1 Receptor Agonist	86
Modified-Release Phosphatidylcholine (LT-02) for Ulcerative Colitis: Two Double-Blind, Randomized, Placebo-Controlled Trials	85
Endoscopic Sleeve Gastroplasty Plus Lifestyle Intervention in Patients With Metabolic Dysfunction-associated Steatohepatitis: A Multicenter, Sham-controlled, Randomized Trial	83
Trends in Etiology-based Mortality From Chronic Liver Disease Before and During COVID-19 Pandemic in the United States	83
Optimizing trial design for evaluating combination therapies in IBD	83
Prevalence of Gastric Precursor Lesions in Countries With Differential Gastric Cancer Burden: A Systematic Review and Meta-analysis	82
The Impact of the Social Determinants of Health on Disparities in Inflammatory Bowel Disease	82
Daily or Twice Daily Treatment With Topical Steroids Results in Similar Responses in Eosinophilic Esophagitis	81
Associations Between Sexual Orientation and Disorders of Gut-Brain Interaction in Sexual Minority Populations	81
AI-Assisted Capsule Endoscopy for Detection of Ulcers and Erosions in Crohn’s Disease: A Multicenter Validation Study	80
Fecal Microbiota-Based Therapies Compared to Fecal Microbiota Transplantation for Preventing Recurrent C difficile Infection	79
A Novel, Noninvasive Method to Diagnose Active Eosinophilic Esophagitis, Combining Clinical Data and Oral Cavity RNA Levels	78
Chronic Kidney Disease Does Not Influence Response to Terlipressin in Hepatorenal Syndrome–Acute Kidney Injury	78
Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA	77
AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Patients With Malignancy: Commentary	76
Perianal Disease in Pediatric-Onset Crohn’s Disease: Incidence, Disease Course, and Long-Term Outcomes	75
Genetic Diagnosis Guides Treatment of Autoimmune Enteropathy	75
Effect of Five Dietary Emulsifiers on Inflammation, Permeability, and the Gut Microbiome: A Placebo-controlled Randomized Trial	73
Fibrosis-4 Index Predicts Long-Term All-Cause, Cardiovascular and Liver-Related Mortality in the Adult Korean Population	73
AGA Clinical Practice Update on New Technology and Innovation for Surveillance and Screening in Barrett’s Esophagus: Expert Review	71

Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-analysis	71
Table of Contents	70
Reply	70
Blue Notes	70
Editorial Board	69
Front Cover	69
Acute-onset Type 1 Diabetes Mellitus and Pancreatic Atrophy Caused by an Immune Checkpoint Inhibitor	68
Continuing the Commitment to Diversity, Equity, and Inclusion Within AGA Journals	68
Response to “Recent Advancements and Future Perspectives of Per Oral Endoscopic Myotomy”	67
Reply	67
Low Colorectal Cancer Risk After Resection of High-Risk Pedunculated Polyps	67
Multiple Negative Fecal Immunochemical Tests: Is Testing Really Better?	67
Value of Ammonia Testing in Clinical Practice	66
Upadacitinib in Mothers With Inflammatory Bowel Disease: Placental Transfer and Breast Milk Excretion	66
Direct Oral Anticoagulants in Budd-Chiari Syndrome: Need a Closer Look!	65
Editorial Board	65
Reply	64
Cover	64
Cover	64
The New Kids on the Block: Emerging Complementary Colonoscopy Quality Metrics	64
Reply	64
A Framework for Creating a FOAMed Organization in Gastroenterology: Lessons Learned from the Liver Fellow Network	64
Statins for Chronic Liver Disease and the Need for Randomized Controlled Trials	64
Reply	64
Transient Uterine Prolapse: A Rare Complication of Endoscopic Polypectomy	64
Foaming at the Varix: Sclerotherapy of Esophageal Varices via Intrahepatic Portal Vein Access	64
Reply	62
Clinical Outcomes of Intraductal Papillary Mucinous Neoplasms With Dilatation of the Main Pancreatic Duct	62
Mental Health Diseases Are Associated With Active Hepatitis C and Partly Drive Hepatocellular Carcinoma Trends in Veterans	61
Skills or Pills: Randomized Trial Comparing Hypnotherapy to Medical Treatment in Children With Functional Nausea	61
Environmental Toxins in Breast Milk and Risk of Early Onset Colorectal Cancer	61
The Affordable Care Act Improves Access, Survival, and Racial Disparities of Patients With Liver Disease: A Systematic Review	60
Uptake of Colorectal Cancer Screening in 45 to 49 Year Olds: An Early-Inning View from the Endoscopy Suite	60
Long-Term Outcomes After Endoscopic Submucosal Dissection for T1 Colorectal Cancer: A Multicenter Prospective Study	60
Adenoma Detection Rate and Clinical Characteristics Influence Advanced Neoplasia Risk After Colorectal Polypectomy	60
Bouveret Syndrome Treated With Endoscopic Lithotripsy and Gallbladder Access via Cholecysto-duodenal Fistula	59
Correction	59
Significance of Crypt Atypia in Barrett’s Esophagus: A Clinical, Molecular, and Outcome Study	59
North American Expert Consensus on the Post-procedural Care of Patients After Per-oral Endoscopic Myotomy Using a Delphi Process	58
Harm-to-Benefit Ratio of Fecal Immunochemical Test–Based Screening for Colorectal Cancer Given Prior Fecal Hemoglobin Concentrations	58
Population-based Screening for Hereditary Colorectal Cancer Variants in Japan	58
Gastroparesis and Chronic Pancreatitis: Are They Truly Related?	58
Prior Authorizations Delay Therapy, Impact Decision-making, and Lead to Adverse Events in Inflammatory Bowel Disease: 2022 Provider Survey	58
Extraintestinal Symptoms in Irritable Bowel Syndrome Are Associated With Stress Reactivity and the Gut Microbiome in a Sex-dependent Manner	55
Real-world Comparison of Steatosis-Associated Fibrosis Estimator and Fibrosis-4 Scores for Assessing Metabolic Dysfunction-associated Steatotic Liver Disease-related Fibrosis in a Highly Diverse Urban	55
Longitudinal Fecal Calprotectin Profiles Characterize Disease Course Heterogeneity in Crohn’s Disease	54
Development and Validation of a Noninvasive Model for the Detection of High-Risk Varices in Patients With Unresectable Hepatocellular Carcinoma	54
Diverticulosis Is Associated With Internal Hemorrhoids on Colonoscopy: Possible Clues to Etiology	54
Development of a Practical Guide to Implement and Monitor Diet Therapy for Eosinophilic Esophagitis	54
Needle Track Seeding After Trans-gastric EUS-guided Tissue Sampling: Maybe Not as Rare as You Think	53
Front Cover	53
From Onboarding to Excellence: Creating Gastroenterology Advanced Practice Provider Fellowship Programs That Benefit Practices, Patient Access, and Specialty Growth	53
A Randomized, Controlled Trial of Efficacy and Safety of Cannabidiol in Idiopathic and Diabetic Gastroparesis	52
Birth Cohort Colorectal Cancer (CRC): Implications for Research and Practice	52
An Unusual Complication of Endoscopic Ultrasound-Guided Transgastric Liver Biopsy	52
Long-Term Proton Pump Inhibitor Use: Review of Indications and Special Considerations	51
Continuous Risk Score Predicts Waitlist and Post-transplant Outcomes in Hepatocellular Carcinoma Despite Exception Changes	51
Diet and Microbiome-Directed Therapy 2.0 for IBD	51
Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis	50
Prolonged Gastrointestinal Manifestations After Recovery From COVID-19	50
Personalized (N-of-1) Clinical Trials for Inflammatory Bowel Disease: Opportunities and Challenges	50
Prediction of Relapse After Anti–Tumor Necrosis Factor Cessation in Crohn’s Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies	50
All-cause and Cause-specific Mortality in Achalasia: A Nationwide Matched Cohort Study	50
Adjunctive GLP1 Receptor Agonists in Patients With Inflammatory Bowel Diseases and Obesity and/or Diabetes: A Target Trial Emulation	50
Metabolic Dysfunction-Associated Steatotic Liver Disease Facilitates Hepatitis B Surface Antigen Seroclearance and Seroconversion	49
Assessing Diagnostic Performance of Modifications to the Rome IV Criteria for Irritable Bowel Syndrome	49
Birth Cohort Effects on Colorectal Cancer Onset in Lynch Syndrome	49
Drug-induced Liver Injury in Latin America: 10-year Experience of the Latin American DILI (LATINDILI) Network	49
The EXTENT Study: Results From an International Expert Delphi Consensus to Define Ultrasonographic Parameters for Measuring Bowel Damage in Crohn’s Disease	49
Upadacitinib Achieved Rapid Response in Biologic-Refractory Immune Checkpoint Inhibitor-Related Enterocolitis	49
The Severity of Reduced Esophageal Distensibility Parallels Eosinophilic Esophagitis Disease Duration	49
Reply	49
Preoperative Hepatology and Primary Care Visits Improve Postoperative Outcomes in Patients With Cirrhosis Undergoing Surgery	49
Risk of Advanced Colorectal Neoplasia at Follow-up Colonoscopy After Synchronous Adenoma and Clinically Significant Serrated Polyp	48
Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of the Art Update	48
Front Cover	48
Colon Volume by Computed Tomography and Scintigraphic Colonic Transit in Constipated Patients With or Without Redundant Colon	48
Real-World Surgical and Endoscopic Recurrence Based on Risk Profiles and Prophylaxis Utilization in Postoperative Crohn’s Disease	48
Editorial Board	48
Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis	48

Perianal Fistulizing Crohn’s Disease–Associated Anorectal and Fistula Cancers: Systematic Review and Expert Consensus	48
Editorial Board	48
Reply	48
Antibiotic Use and Later Risk of Celiac Disease: A Nationwide Case-Control and Sibling Analysis	47
Prevalence of Liver Steatosis and Fibrosis in Adults With Primary Hypobetaliproteinemia: Results From the HYPOCHOL Study	47
Prevalence of Chronic Liver Disease in Cholangiocarcinoma: A Meta-Analysis	47
Disparities in Colorectal Cancer Screening Among Asian American Populations and Strategies to Address These Disparities	47
Endoscopic Submucosal Dissection for Esophageal Squamous Cell Carcinoma With Varices Using Red Dichromatic Imaging	46
Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat	46
Nature and Nurture in Familial Aggregation of Steatotic Liver Disease	46
Declines in Colorectal Cancer Incidence and Mortality Rates Slow Among Older Adults	46
Blue Notes	45
Reply	45
Adult-Onset Fontan Circuit Failure: A Rare Cause of Protein-Losing Enteropathy	45
Reply	45
Reply	45
Patient Navigation Increases Linkage to Care and Receipt of Direct-acting Antiviral Therapy in Patients with Hepatitis C	44
Reply	44
Editorial Board	44
Blue Notes	44
Front Cover	44
Decreasing Case Fatality Rates for Patients With Cirrhosis Infected With SARS-CoV-2: A National COVID Cohort Collaborative Study	44
Elsewhere in the AGA Journals	44
Reply	44
Gastric Emptying, Colon Filling, and Multiregional Gut Transit Delays Are Prevalent on Glucagon-Like Peptide-1 Agonists	43
Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel Disease	43
To Stop or Not to Stop? Predicting Relapse After Anti-TNF Cessation in Patients With Crohn’s Disease	43
Letter Response to: Hernandez-Rocha C et al, Clin Gastroenterol Hepatol 2024	43
Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases	43
Preparing the Next Generation of Gastroenterologists to Tackle Climate Change	42
Prediction of Postoperative Recurrence in Crohn’s Disease: Where Do We Go From Here?	42
Ustekinumab and Vedolizumab Safety and Clearance in Pregnancy With Inflammatory Bowel Disease: Stop the Disease, Not the Drug!	42
Diffuse Large B-Cell Duodenal Lymphoma Presenting With Obstruction and Pneumatosis	42
Elsewhere in the AGA Journals	42
Dietary Fiber is Associated With Decreased Risk of Gastroesophageal Reflux Symptoms	41
Real-World Effectiveness of Lenvatinib in Hepatocellular Carcinoma Patients with Nonalcoholic Steatohepatitis	41
Hepatitis B RNA and Core-Related Antigen Provide Value Beyond DNA in Evaluating e But Not Surface Antigen Clearance	41
Reply	41
Abdomino-anal Dyscoordination in Defecatory Disorders	41
Establishing an Endobariatric Practice: Steps, Challenges, and Considerations Within a Private Practice Model	41
Reply	41
Is Baseline Metabolic Dysfunction-associated Steatohepatitis Fibrosis the Key Determinant for Survival After Bariatric Surgery?	41
Reduction in Racial and Ethnic Disparity in Survival Following Liver Transplant for Hepatocellular Carcinoma in the Direct-acting Antiviral Era	41
Internal Hernia and Volvulus After Endoscopic Ultrasound-guided Gastrojejunostomy	41
Table of Contents	40
Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study	40
Reply	40
Unaddressed Limitations of Alanine Aminotransferase as a Screening Tool for Pediatric Advanced Metabolic Dysfunction-Associated Steatotic Liver Disease	40
Impact of Chronic Hepatitis B and Its Clinical Phases on Liver Fibrosis and Cirrhosis in Metabolic Dysfunction-Associated Steatotic Liver Disease	40
Crafting a Therapeutic Pyramid for Eosinophilic Esophagitis in the Age of Biologics	40
Knowledge, Attitudes, and Environment Related to Gastroenterology and Hepatology Care for Sexual and Gender Minorities	39
Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis	39
Safety of Vedolizumab and Ustekinumab Compared With Anti-TNF in Pregnant Women With Inflammatory Bowel Disease	39
Upadacitinib Was Efficacious and Well-tolerated Over 30 Months in Patients With Crohn’s Disease in the CELEST Extension Study	39
Symptom Classes in Decompensated Liver Disease	39
Baseline Hepatitis B Virus Surface Antigen Titers in Childhood Predict the Risk of Advanced Liver Fibrosis in Adulthood	39
Underestimation of Cirrhosis-Related Mortality in the Medicare Eligible Population, 1999–2018	39
Perceptions, Definitions, and Therapeutic Interventions for Occasional Constipation: A Rome Working Group Consensus Document	39
Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis	38
Interventional Radiological Management for Budd-Chiari Syndrome: A 10-Year Retrospective, Multicenter Survey on 997 Patients in China	38
Association of Physical Activity With Risk of Liver Fibrosis, Sarcopenia, and Cardiovascular Disease in Nonalcoholic Fatty Liver Disease	38
Efficacy and Acceptability of Dietary Therapies in Non-Constipated Irritable Bowel Syndrome: A Randomized Trial of Traditional Dietary Advice, the Low FODMAP Diet, and the Gluten-Free Diet	38
Defining Noninvasive Criteria for Indicating Drug Therapy in Metabolic Dysfunction–associated Steatotic Liver Disease in Clinical Practice	38
AGA Clinical Practice Update on Endoscopic Lifting Agents: Commentary	38
Defining Radiological Healing in Perianal Fistulizing Crohn’s Disease: A TOpClass Global Expert Delphi Consensus	38
Contemporary Changes in Etiology for Hepatocellular Carcinoma in Liver Transplantation	38
The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis	37
Supplementing Dietary Fibers With a Low FODMAP Diet in Irritable Bowel Syndrome: A Randomized Controlled Crossover Trial	37
Linked-Color Imaging Detects More Colorectal Adenoma and Serrated Lesions: An International Randomized Controlled Trial	37
An Expert Consensus Delphi Panel in Metabolic Dysfunction- and Alcohol-associated Liver Disease: Opportunities and Challenges in Clinical Practice	37
Endoscopic Sedation Type During FLIP Panometry Does Not Significantly Impact FLIP Motility Classification Relative to Manometry	37
A Randomized Phase II Study of Efmarodocokin Alfa, an interleukin-22 Agonist, Versus Vedolizumab in Patients With Ulcerative Colitis	37
Elsewhere in the AGA Journals	37
Diagnosis of Retrograde Cricopharyngeus Dysfunction Using High Resolution Impedance Manometry and Comparison With Control Subjects	37
Stepwise Fenestration via Natural Orifice Transluminal Endoscopic Surgery for Symptomatic Polycystic Liver Disease	36
Reply	36
Editorial Board	36
Missed Opportunity to Triage Patients With Irritable Bowel Syndrome to Multidisciplinary Therapy	36
Nomenclature Dilemma of Metabolic Associated Fatty Liver Disease (MAFLD): Considerable Proportions of MAFLD Are Metabolic Healthy	36
Reply	36
Population-Attributable Fractions of Nonalcoholic Fatty Liver Disease on All-Cause and Cause-Specific Mortality Risk: How Large is the Impact?	36
Front Cover	36
How to Train the Next Generation to Provide High-Quality Peer-Reviews	36
Reply	36
Blue Notes	36
Bridging the Racial, Ethnic, and Gender Gap in Gastroenterology	35
Collaborative Co-Managed Care (C3): A Sustainable Gastrointestinal Motility Practice Model	35
2024 Reviewer Recognition	35
Correction	35
Earlier Anti-TNF Initiation Leads to Long-term Lower Health Care Utilization in Crohn’s Disease but Not in Ulcerative Colitis	35
Impact of Time Period and Birth Cohort on the Trend of Advanced Neoplasm Prevalence in the 40–49 Average-Risk Screening Population	35
Disease Progression Modeling for Economic Evaluation in Nonalcoholic Fatty Liver Disease—A Systematic Review	35
Influence of Low-dose Acetylsalicylic Acid on Renal Function in Patients With Liver Cirrhosis and Ascites	35
Re-evaluating the Proposed Association Between Vonoprazan and Gastric Cancer Following Eradication of H. pylori Infection	34
Nationally Automated Colonoscopy Performance Feedback Increases Polyp Detection: The NED APRIQOT Randomized Controlled Trial	34